Fludarabine

Catalog No.S1491 Synonyms: FaraA, Fludarabinum

Fludarabine Chemical Structure

Molecular Weight(MW): 285.23

Fludarabine is a STAT1 activation inhibitor which causes a specific depletion of STAT1 protein (and mRNA) but not of other STATs. Also a DNA synthesis inhibitor in vascular smooth muscle cells.

Size Price Stock Quantity  
In DMSO USD 126 In stock
USD 97 In stock
USD 310 In stock
USD 470 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • ERK signaling regulates STAT1 phosphorylation, and pSTAT1 modulates MHC II expression in the spinal cord under BCP conditions. AG490 (5 μg in 10 μL), Fludarabine (10 μg in 10 μL), or U0126 (5 μg in 10 μL) was intrathecally injected into cancer-bearing rats once a day for 14 days, beginning immediately after carcinoma cell inoculation (n = 3 in each group). (A) Representative western blot showing pSTAT1ser727, total STAT1, pERK42/44, total ERK42/44, CIITA, MHC II RTIB, and b actin protein levels in the spinal cords of BCP rats.

    Brain Behav Immun, 2017, 60:161-173. Fludarabine purchased from Selleck.

    Imatinib mesylate (IM) in combination of fludarabine phosphate (F-AMP) significantly inhibits Ki67 and c-KIT expression in GIST-T1 tumor xenografts. Tumors were collected on the day after the last treatment and were then subjected to immunohistochemical detection of Ki67 and c-KIT expression. Representative images of immunohistochemical staining of Ki67 and c-KIT in mice tumors.

    Mol Cancer Ther, 2014, 13(10): 2276-87 . Fludarabine purchased from Selleck.

  • Normal human KC pretreated with STAT1 inhibitor (fludarabine [10 uM]) or STAT3 inhibitor (STA-21 [2 uM]) for 24 h. The mRNA levels of hBD2 and hBD3 were assessed by qRT-PCR.

    Mol Cell Biol 2014 34(24), 4368-78.. Fludarabine purchased from Selleck.

    Bacterial infection in IPEC-J2 cells. The invasion and attachment of EHECO157:H7 was increased in the IPEC-J2 cells in the presence of 10 μM fludarabine. Data are expressed as the mean ± SEM (n= 6). Differences between groups were determined by paired samples t-test. *P<0.05 compared with the control.

    Int Immunopharmacol, 2016, 36:199-204.. Fludarabine purchased from Selleck.

Purity & Quality Control

Choose Selective STAT Inhibitors

Biological Activity

Description Fludarabine is a STAT1 activation inhibitor which causes a specific depletion of STAT1 protein (and mRNA) but not of other STATs. Also a DNA synthesis inhibitor in vascular smooth muscle cells.
Targets
STAT1 [4]
(Vascular smooth muscle cells)
In vitro

Fludarabine efficiently inhibits the proliferation of RPMI 8226 cells with IC50 of 1.54 μg/mL. The IC50 of Fludarabine against MM.1S and MM.1R cells is 13.48 μg/mL and 33.79 μg/mL, respectively. In contrast, U266 cells are resistant to Fludarabine with IC50 of 222.2 μg/mL. Fludarabine treatment results in increased number of cells in the G1 phase of cell cycle, accompanied with a concomitant reduction of cells at the S phase of cell cycle in a time-dependent manner. Fludarabine induces a cell cycle block and triggers apoptosis in MM cells. Fludarabine triggers time-dependent cleavage of caspase-8, -9, and -3, -7, followed by PARP cleavage. Fludarabine increases expression of Bax in a time-dependent fashion, while the expression of Bak doesn't change. After exposure to Fludarabine for 12 hours, RPMI 8226 cells shows a loss of membrane potential with 61.05% of the cells expressing low fluorescence of rhodamine 123 compared with 8.62% of cells in untreated control. [1] To enhance solubility, Fludarabine is formulated as the monophosphate (F-ara-AMP, fudarabine), which is instantaneously and quantitatively dephosphorylated to the parent nucleoside upon intravenous infusion. Inside the cells rephosphorylation occurs which leads to fuoroadenine arabinoside triphosphate (F-ara-ATP), the major cytotoxic metabolite of F-ara-A. [2] Fludarabine can also induce pro-inflammatory stimulation of monocytic cells, as evaluated by increased expression of ICAM-1 and IL-8 release. [3] Fludarabine does not affect the growth of ovarian cancer cell lines, whereas it induces marked and dose-dependent inhibition of proliferation in melanoma cell lines. [4] Fludarabine induces significant reduction of STAT-1 phosphorylation, whereas it does not change JAK2 activation. Interestingly, Fludarabine does not significantly affect the phosphorylation of these three STAT proteins. Fludarabine (1.5 mg) significantly prevents STAT-1 phosphorylation and also reduces the increased amount of this protein. No significant changes are demonstrated in JAK2 phosphorylation at 2 days, but Fludarabine inhibits JAK2-increased expression at 7 days. Fludarabine specifically inhibits STAT-1 activation without affecting other STAT proteins and consequently diminishes VSMC proliferation. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Jeko-1  NGGxVnlHfW6ldHnvckBCe3OjeR?= MljlNlAh|ryP Mle5NlQhcA>? NXXLS|R[cW6qaXLpeJMh\XiycnXzd4lwdiCxZjDJSG8> NHrG[XkzPTl2MEexNi=>
MV-4-11 NIHod3FCeG:ydH;zbZMhSXO|YYm= NUjwbms5Oi53IN88US=> M2S1OFQ5KGh? NXrLXHhjcW6mdXPld{BieG:ydH;zbZMhe2yrZ3j0cJk> M4nBb|I2OTFzNUiz
THP-1 MUHBdI9xfG:|aYOgRZN{[Xl? NUHWcJdqOi53IN88US=> MkTnOFghcA>? MoTFbY5lfWOnczDhdI9xfG:|aYOgd4xq\2i2bIm= MVSyOVEyOTV6Mx?=
MOLM 13 MYnBdI9xfG:|aYOgRZN{[Xl? M2izSlIvPSEQvF2= MojOOFghcA>? MontbY5lfWOnczDhdI9xfG:|aYOgd4xq\2i2bIm= M2rW[FI2OTFzNUiz
KBM3/Bu2506 M2LaXWFxd3C2b4Ppd{BCe3OjeR?= NFP0PY4zNjVizszN M4jnTlQ5KGh? MUHpcoR2[2W|IHHwc5B1d3OrczDzcIlocHSueR?= M3rh[VI2OTFzNUiz
Nalm-6 Mke1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTF6IN88US=> MlztNlUxPjFzMEG=
Reh NGDBcGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXuTWM2OD1|MDFOwG0> MWiyOVA3OTFyMR?=
U2937 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTF4IN88US=> MlzsNlUxPjFzMEG=
Mec-1 M1\HbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NICyXJFKSzVy78{eOVAxKM7:TR?= NI\hTWYzPTB4MUGwNS=>
RPMI-8226 NGTkc2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfRTWM2OD13MECg{txO NYj0XWRoOjVyNkGxNFE>
Molt-4 M4Xjbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjmTWM2OD1zOECg{txO NHfYdHozPTB4MUGwNS=>
Nalm-6-FluR NGTVeZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEH1OpVKSzVyPUK1NEDPxE1? NFWyd2ozPTB4MUGwNS=>
Raji  NVXMd|hnTnWwY4Tpc44hSXO|YYm= NVXYPY4zO8LizszN M37FSlI1NzR6L{eyJIg> MXXpcoR2[2W|IHHjZ5VufWyjdHnvcpMhd2ZicEWzMEBxPjNiYX7kJJA4O8Li M4[2XlI1QTRyNkm1
PBMC Mnr3SpVv[3Srb36gRZN{[Xl? NUjwcJZwPTBxMUCwJO69VQ>? M3TDXlI1KGh? Ml;6SG1UVw>? MV3pcohq[mm2czDTWGFVOSCyaH;zdIhwenmuYYTpc44> MlThNlQ6OTF6N{K=
MDA-231 M135eWZ2dmO2aX;uJGF{e2G7 Ml;ZNVAxKM7:TR?= NHHDfVUzPCCq NV\ZTZhNTE2VTx?= NXOxdW5s\GWlcnXhd4V{KEmGTzDlfJBz\XO|aX;u NW\rNVFQOjR7MUG4O|I>
624.38mel  MW\GeY5kfGmxbjDBd5NigQ>? MVS1NEDPxE1? MVyyOEBp MXvEUXNQ MX;k[YNz\WG|ZYOgTWRQKGW6cILld5Nqd25? NIS3cGEzPDlzMUi3Ni=>
MDA-231 MmfMSpVv[3Srb36gRZN{[Xl? NHzDdI82OC1{MECg{txO NVTRbJF{OjRiaB?= NEWwRmxFVVOR NFTpUW9qdmirYnn0d{BKTE9iYXP0bZZqfHliaX7k[ZBmdmSnboTsfUBw\iCvUl7BJIxmfmWucx?= NFXFOoozPDlzMUi3Ni=>
624.38mel  Ml7oSpVv[3Srb36gRZN{[Xl? MX21NE0zODBizszN NUjXXmcyOjRiaB?= NWH1b|ZJTE2VTx?= MXXpcohq[mm2czDJSG8h[WO2aY\peJkhcW6mZYDlcoRmdnSueTDv[kBuWk6DIHzleoVtew>? MUWyOFkyOTh5Mh?=
HMECs Mkj6SpVv[3Srb36gRZN{[Xl? MlfsNVAxyqEQvF5CpC=> M1f2d|M3yqCq NUnQd4FVcW6qaXLpeJMhUU[QzsRCpIFv\CCOUGOgbY5lfWOnZDDTWGFVOSCyaH;zdIhwenmuYYTpc44h[W6mIFnSSlEh\XiycnXzd4lwdg>? NHv3PYozPDJzMUOyOy=>
HMECs  NULvSZE3TnWwY4Tpc44hSXO|YYm= MlHzNVAxyqEQvF5CpC=> M1XaU|M3yqCq MVXpcohq[mm2czDJSm7PucLibXXkbYF1\WRicHjvd5Bpd3K7bHH0bY9vKG:oIGPURXQyKGGwZDDTWGFVOyxiYoX0JI5wfCCxZjDTWGFVOg>? NGXGTJgzPDJzMUOyOy=>
BJAB MoPoRZBweHSxc3nzJGF{e2G7 NXrRbldxPcLizszN MkflNlQhcA>? NUL5XIh5cW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= MYeyOFA2PzF2Nx?=
I-83 NYe5fY9tSXCxcITvd4l{KEG|c3H5 NIqzcYk2yqEQvF2= M1fCclI1KGh? NXnG[oNHcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= MnvKNlQxPTdzNEe=
NALM6 M2[5N2Fxd3C2b4Ppd{BCe3OjeR?= NVrUfVVQPcLizszN M1\0[|I1KGh? Mlm4bY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NWXlXIM4OjRyNUexOFc>
DU-145 NWGycYVHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrUWFlwOC1zMDFOwIcwdWx? M3q2VFQ5KGkEoB?= MnzFbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NIC2fWczOzd|NEixOS=>
Nalm-6 MXnGeY5kfGmxbjDBd5NigQ>? Ml;LNVDDqM7:TR?= MoDRNU8zNzRiaB?= M{nXVIlv\HWlZYOgZZV1d3CqYXf5 MmflNlM3QDF{MkO=
Reh MVfGeY5kfGmxbjDBd5NigQ>? MkjYNVDDqM7:TR?= MVyxM|IwPCCq M1zEPYlv\HWlZYOgZZV1d3CqYXf5 NY\ncG53OjN4OEGyNlM>
Nalm-6 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxKOLKvEGw5qCK|ryP M1\ONVI{PjhzMkKz
Reh NXzhTVVyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIX3WHBKSzVyIPMIwFEx6oDLzszN MkTlNlM3QDF{MkO=
HEC1A NIG1UFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYX6WI9HOTByLUWwNEDPxE1? M4DZZVI1KGh? NHHFVnJqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NX\4coxWOjN3OUW2PVc>
AN3CA NYK1dXZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTnb2ZlOTByLUWwNEDPxE1? MlixNlQhcA>? M3HwT4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NHvYO24zOzV7NU[5Oy=>
HEC50B Mor2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LGbVExOC13MECg{txO M2DncVI1KGh? MVTpcohq[mm2czDj[YxtKGe{b4f0bEB{dGmpaITsfS=> Ml3wNlM2QTV4OUe=
HEC1A M3vjU2Fxd3C2b4Ppd{BCe3OjeR?= MXuyNE8yODBizszN NHy1WJQzPCCq MorPbY5lfWOnczDhdI9xfG:|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MoXlNlM2QTV4OUe=
AN3CA NFHrNIVCeG:ydH;zbZMhSXO|YYm= NXfn[FVwOjBxMUCwJO69VQ>? NHvWWVUzPCCq M3\C[olv\HWlZYOgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MWeyN|U6PTZ7Nx?=
HEC50B M4rVcWFxd3C2b4Ppd{BCe3OjeR?= M33XdlIxNzFyMDFOwG0> MmHwNlQhcA>? Ml7SbY5lfWOnczDhdI9xfG:|aYOgd4xq\2i2bIm= NITTcI8zOzV7NU[5Oy=>
EHEB MnqxRZBweHSxc3nzJGF{e2G7 M3e3PFQxKM7:TR?= MkHVNlQhcA>? NGDNd3pqdmS3Y3XzJIFxd3C2b4Ppdy=> NIHVN40zOzR7N{C3OS=>
A549 MmnPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTF3LkhCtVIvQCEEtV2= MmfpNlM{PzdzOUK=
A549 GAPDH-deficient MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTIcm96UUN3ME2xPE42yrF{LkOgxtVO MYGyN|M4PzF7Mh?=
CLL  NHPvZo5CeG:ydH;zbZMhSXO|YYm= NFrhfoYyOCEQvF5CpC=> M1XGcVI1NTl4IHi= NHfxWIpqdmS3Y3XzJIFxd3C2b4TpZ{Bk\WyuIHTlZZRp NWPNRoxiOjJ{MEe2PFY>
MEC1 MUfBdI9xfG:|aYOgRZN{[Xl? MXSxNFDDqM7:TR?= Ml3sO|IhcA>? M1;HW4lv\HWlZYOgZZBweHSxc3nzJJNq\26rZnnjZY51dHl? MX:yNlE{Ojl5Mx?=
U937  MV7BdI9xfG:|aYOgRZN{[Xl? M2GxOlAvQCEQvF2= NFvqUlc1NTR6IHi= M{LwWYlv\HWlZYOgZZBweHSxc3nzJJNtcWeqdHz5 MViyNlA4PDdyMB?=
U937  MUHBdI9xfG:|aYOgRZN{[Xl? MYOxJO69VQ>? M3;HTlk3KGh? M{nXSolv\HWlZYOgZZBweHSxc3nzJJNtcWeqdHz5 M4rYXVIzODJ|NUKz
Daudi MoHiRZBweHSxc3nzJGF{e2G7 M3LmclIxKM7:TR?= MVO5OkBp M1\0cIlv\HWlZYOgZZBweHSxc3nzJJNtcWeqdHz5 M4PlO|IzODJ|NUKz
J45.01 Mki1RZBweHSxc3nzJGF{e2G7 NVnzR|NDOSEQvF2= MkP2PVYhcA>? MmTqbY5lfWOnczDhdI9xfG:|aYOgd4xq\2i2bIm= NEf1flQzOjB{M{WyNy=>
RPMI 8226 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3ThdWlEPTB;MkWuPeKhyrIEoEOuO{DPxE1? M{XEZ|IyQTR6Mk[0
CEM Ml7xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEGzOIhKSzVyPUKuOOKhyrIEoECuOEDPxE1? M2e4SVIyQTR6Mk[0
Raji NVjmZo9CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGr0cZZKSzVyPUCuOFfDqMLzwrCwMlA1KM7:TR?= M3;4e|IyQTR6Mk[0
U937 NIniTFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NImySY9KSzVyPUCuNlTDqMLzwrCwMlA1KM7:TR?= M{PIOFIyQTR6Mk[0
K562 NGXYeGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIr6UWxKSzVyPUCuOFTDqMLzwrCwMlA2KM7:TR?= MlixNlE6PDh{NkS=
NALM-6 NIrFXItCeG:ydH;zbZMhSXO|YYm= M1ToVlExKM7:TdMg NFXZNIMzPCCq Mk\tbY5lfWOnczDj[YxtKGGyb4D0c5NqeyC|bHnnbJRtgQ>? NGXnboIzOTZ7OUO4Ny=>
JMV-3 MX\BdI9xfG:|aYOgRZN{[Xl? MlP5NVAh|ryPwrC= MUOyOEBp MYnpcoR2[2W|IHPlcIwh[XCxcITvd4l{KHOuaXfoeIx6 M360O|IyPjl7M{iz
EHEB M36xWmZ2dmO2aX;uJGF{e2G7 MVu1MVUxKM7:TR?= Mnv6NlQhcA>? NYnEbFM2\GWlcnXhd4V{KHB{MTDlfJBz\XO|aX;uJJNq\26rZnnjZY51dHl? M3rlZVIyOTZ6M{mx
JVM-2  MV7GeY5kfGmxbjDBd5NigQ>? MYWzNEDPxE1? NV\Kc4tROjRiaB?= Mlrp[IVkemWjc3XzJJAzOSCneIDy[ZN{cW:w NHjHS4UzOTF4OEO5NS=>
KBM3/Bu2506 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|IxRTBwNkegxtVO MWeyNFk{OzVyOR?=
KBM3/Bu2506 M3\0Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH60d|ExNjZizszN MnLZNlQhcA>? M3XyPIlv[3KnYYPld{B1cGViY3XscEBnemGldHnvckBqdiCVLYDoZZNm M3jKU|IxQTN|NUC5
MDA-MB-231 Mn3jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTMO3dKSzVyPUSuNEDPxE1? MlnZNlA1PDd|OUC=
MCF-7 M4TwW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M36yU2lEPTB;MUWuNEDPxE1? MVOyNFQ1PzN7MB?=
HLE-B3  MWXGeY5kfGmxbjDBd5NigQ>? MVeyOUDPxE1? M2XnNFQ5KGh? NYfVdlRt[myxY3vzJGlHVi4Qs,MAl4lv\HWlZXSgV3RCXDFicHjvd5Bpd3K7bHH0bY9vKGGwZDDJSG8h\XiycnXzd4lwdg>? NFPzTmEzODR|NUG1PC=>
K562 M4qwd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVm3NkBp M1zITWlEPTB;Mz6zJI5O MV:yNFMxPzF7OB?=
BW-225 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nQRWlEOjB;MT6zO{DEnzFy4pkSPOKh|ryPwrC= NV[4eFFtOTh4NkGzPFA>
OH-65 Mlv2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{frd2lEOjB;MT6zO{DEnzFy4pkSPOKh|ryPwrC= MV2xPFY3OTN6MB?=
GR-145 M1HKVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;lb2hWUUN{ME2yMlc1KMPZIEGw5qiTQCBizszNxsA> NUXn[lhZOTh4NkGzPFA>
A549 MmLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|IxRTVwNEigx7chOTEkiKK4JO69VcLi NHezOoQyQDZ4MUO4NC=>
CaSki  MlXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|IxRTFwM{egx7chOTEkiKK3JO69VcLi MX:xPFY3OTN6MB?=
ZMK-1 Mk\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXzWoJKSzJyPUGuN|chy5diMUFijLI3KM7:TdMg Ml;UNVg3PjF|OEC=
SKW6.4 Mmf2RZBweHSxc3nzJGF{e2G7 M{Dm[lAvODFvMUCg{txO NVfvOYhKOjRxNEigbC=> MYjpcoR2[2W|IHPlcIwh\GWjdHigbY4h[m:2aDD0bY1mNSCjbnSg[I9{\S1iZHXw[Y5l\W62IH3hco5meg>? MUSxPFA6OjN2MB?=
RPMI 8226 NXfl[YY{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnCUlhXOjRiaB?= NGTnNoZKSzVyPUGuOVTDqM7:TR?= M1HFU|E4QTd4MUi2
MM.1S NGe4cpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7YUpQ1QCCq MUnJR|UxRTF|LkS4xsDPxE1? MoTpNVc6PzZzOE[=
MM.1R NGXkTlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\YOFghcA>? MneyTWM2OD1|Mz63PUDPxE1? NYXzXmk6OTd7N{[xPFY>
U937 NFn5[IFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HteGlEPTB;MzyyNFAhyrFiNU[wJI5O MnPyNVU6OzB|NkG=

... Click to View More Cell Line Experimental Data

In vivo Tumors treated with PBS grow rapidly to approx-imately 10-fold their initial volume in 25 day, whereas, the tumors in the Fludarabine at 40 mg/kg increase less than 5-fold. A significant antitumor effect of 40 mg/kg Fludarabine on RPMI8226 tumor growth is demonstrated. RPMI8226 tumors treated with 40 mg/kg Fludarabine at day 10 increase apoptotic nuclei. Fludarabine is effective in suppressing RPMI8226 myeloma xenografts in SCID mice. [1]

Protocol

Cell Research:

[1]

+ Expand
  • Cell lines: Dexamethasone-sensitive (MM.1S) and -resistant (MM.1R) human MM cell lines, RPMI8226 and U266 cell lines
  • Concentrations: 2 μg/mL
  • Incubation Time: 24 hours
  • Method:

    After treated with Fludarabine or control, dexamethasone-sensitive (MM.1S) and -resistant (MM.1R) human MM cell lines, RPMI8226 and U266 cell lines (5 × 105 cells) are washed twice in phosphate-buffered saline (PBS) and fixed with 70% ice-cold ethanol, then centrifuged and suspended in PBS containing 100 μg/mL RNase A. After incubated for 30 minutes at 37 ºC, samples are resuspended in 25 μg/mL propidium iodide. Flow cytometry is performed on a FACSCalibur automated system. Apoptosis is determined by Annexin V-FITC apoptosis detection kit, according to the manufacturer's instructions. For TUNEL (terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling) assay, cells are analyzed by flow cytometry using the in situ cell death detection kit.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Severe combined immunodeficient (SCID) mice bearing RPMI 8226 cells
  • Formulation: PBS
  • Dosages: 40 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 57 mg/mL (199.83 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
30% propylene glycol, 5% Tween 80, 65% D5W
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 285.23
Formula

C10H12FN5O4

CAS No. 21679-14-1
Storage powder
Synonyms FaraA, Fludarabinum

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01585415 Terminated Metastatic Cancer|Melanoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 9, 2012 Phase 1
NCT01503242 Recruiting Plasma Cell Myeloma|Refractory Plasma Cell Myeloma Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI) January 9, 2012 Phase 1
NCT01319565 Active, not recruiting Metastatic Melanoma|Skin Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) March 9, 2011 Phase 2
NCT01145209 Active, not recruiting Small Lymphocytic Lymphoma|CLL (Chronic Lymphocytic Leukemia) National Heart, Lung, and Blood Institute (NHLBI)|University of Virginia|GlasoSmithKline|National Institutes of Health Clinical Center (CC) June 9, 2010 Phase 2
NCT02500576 Recruiting Melanoma M.D. Anderson Cancer Center|Merck Sharp & Dohme Corp.|Prometheus Inc. August 7, 2015 Phase 2
NCT01174121 Recruiting Metastatic Colorectal Cancer|Metastatic Gastric Cancer|Metastatic Pancreatic Cancer|Metastatic Hepatocellular Carcinoma|Metastatic Cholangiocarcinoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 7, 2010 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    how to re-suspend and deliver the inhibitor for in vivo experiments?

  • Answer:

    For S1491, Fludarabine, we tested a vehicle: 30% Propylene glycol, 5% Tween 80, 65% D5W that you can resuspend the compound in at up to 30mg/ml. It's a suspension and can only be given via oral gavage.

Related Antibodies

STAT Signaling Pathway Map

Related STAT Products

Tags: buy Fludarabine | Fludarabine supplier | purchase Fludarabine | Fludarabine cost | Fludarabine manufacturer | order Fludarabine | Fludarabine distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID